2019 ◽  
pp. 1-6
Author(s):  
Bepasha Naznin ◽  
Md. Ashraful Hoque* ◽  
Daanish Arefin Biswas ◽  
Tamanna Afroz ◽  
Farida Parvin ◽  
...  

Background:Allergic transfusion reactions (ALTR) are very common complication of blood transfusion. Advances in transfusion medicine have significantly decreased the incidence of ALTR; however, ALTR continue to be burdensome for transfusion dependent patients. It increases their existing sufferings. Allergic reaction is more common in platelet concentrate transfusion because stored platelet concentrate supernatants (PCSNs) accumulate striking levels of biological response modifiers (BRMs) during storage. Objective: To determine the risk factors of allergic reactions in platelate concentrate transfusion. Method: It is a case control study enrolled a total of 64 diagnosed case of aplastic anaemia receiving transfusion of platelet concentrate at Department of Transfusion Medicine, BSMMU, Dhaka, from May 2015 to April 2016. Among them 32 case of aplastic anaemia having allergic reaction due to transfusion of platelet concentrate was considered as group I (case) and rest 32 patients not developed allergic transfusion reaction due to transfusion of platelet concentrate was considered as group II (control). Patients age belong to 5 - 50 years and both sex and also patients getting transfusion of plate late concentrate were enrolled in this study. Statistical analysis: Statistical analyses were carried out by using the Statistical Package for Social Sciences version 20.0 for Windows (SPSS Inc., Chicago, Illinois, USA). Chi-Square test, Odds ratio with 95% CI used to analyze the categorical variables, shown with cross tabulation. Student ttest used for continuous variables. Significant value of 'p' was decided to be at a level of 0.05 in two tailed tests. Result: The mean age was found 22.1±11.58 years in group I and 23.5±3.8 years in group II. Twenty four (75.0%) patients were male in group I and 17(53.1%) patients in group II. Almost twenty (62.5%) patients come from urban area in group I and 19(59.4%) in group II. In group I, thirty two (100.0%) patients had urticarialrash, 100.0% had itching, 37.5% had angioedema, 3.1% had cough, 3.1% had chest pain, 3.1% had respiratory distress, 3.1% had fever and 3.1% had vomiting. Almost twenty(62.5%) patients had tachycardia (>100 bpm) in group I and all patients had normal pulse in group II.Thirty two (100.0%) patients had normal blood pressure in both group. In group I, 31(96.9%) patients developed mild allergic reaction, 3.1% moderate allergic reaction. Majority (40.6%) patients belonged to age 16-30 years in present allergic transfusion reaction and 11(34.3%) in absent allergic transfusion reaction. Most (40.6%) of the patients was found blood group B in present allergic transfusion reaction and 11(34.4%) in absent allergic transfusion reaction. Multiple unit of PC transfusion increases 3.69 times risk to develop allergic transfusion reactions with 95% CI 0.99 to 14.44%.Platelet concentrate storage>3daysincreases 5.95timesrisktodevelopallergic transfusionreactionwith95%CI1.75to21.09%. Conclusion: Multiple unit (≥2) transfusion and Platelet concentrate storage >3 days were significantly (p<0.05) associated with allergic transfusion reactions but no significant association was found between allergic transfusion reactions with age and Blood group


Vox Sanguinis ◽  
2009 ◽  
Vol 96 (3) ◽  
pp. 271-271 ◽  
Author(s):  
J.-O. Bay ◽  
O. Tournilhac ◽  
É. Ducher ◽  
J.-P. Romaszko ◽  
A. Ergani ◽  
...  

2017 ◽  
Vol 7 (1) ◽  
Author(s):  
Chathupa Wickremaarachchi ◽  
Elizabeth McGill ◽  
Annmarie Bosco ◽  
Giselee Kidson-Gerber

The aim of this study was to improve current transfusion practice in transfusiondependent thalassaemia patients by determining whether safe transition from triplewashed red cells (TWRC) to leucodepleted red cells (LDRC), increasing transfusion rates, reducing the use of frusemide and creating uniform practice across patients is possible. In patients receiving regular transfusions (50), triple-washed red blood cells were changed to LDRC, transfusion rates were increased to 5 mL/kg/h (in line with the Cooley’s Foundation guidelines) to a maximum of 300 mL/h and frusemide was ceased. Medical review occurred at completion of the transfusion. Of the 20 patients on TWRC, 18 were transitioned to leucodepleted red cells (90%). Recurrent allergic reactions in 2 patients required re-institution of TWRC. 7 of the 8 patients on regular frusemide ceased this practice with no documented transfusion-related fluid overload. One patient refused. Of the eligible 50 patients, 20 patients (40%) were increased to the maximum transfusion rate of 300 mLs/h; 6 (12%) increased rate but refused to go to the maximum; 9 (18%) refused a change in practice and 15 (30%) were already at the maximum rate. There was only one documented transfusion reaction (palpitations) however this patient was able to tolerate a higher transfusion rate on subsequent transfusions. Thalassemia patients on TWRC were safely transitioned to LDRC. Transfusion rates were safely increased, with a calculated reduction in day-stay bed time of 17.45 h per month. This confirms a guideline of 5 mL/kg/h for transfusion-dependant thalassaemia patients with preserved cardiac function is well tolerated and may be translated to other centres worldwide. 本研究的目的是通过确定是否有可能进行从三洗红细胞(TWRC)到去白细胞红细胞(LDRC)的安全过渡,提高输血速率,减少速尿的使用,并在患者中实施统一规则,从而改进输血依赖型地中海贫血患者中现有的输血实践。在接受定期输血的患者(50例)中,将三洗红细胞改为 LDRC,输血速率提高至5 mL/kg/h(符合库利氏贫血基金会的指引),最高可达到300 mL/h,并停止使用速尿。输血完成后进行体检。在使用TWRC的20例患者中,18例转为去白细胞红细胞(90%)。2例患者产生的复发性过敏反应需要重新输以TWRC。8名定期使用速尿的患者中,7名中止了使用该药物,并且没有输血相关液体超负荷的相关记录。一名病人拒绝。在符合条件的50例患者中,20例(40%)增加至300 mL/h的最大输血速率;6例(12%)输血速率提高但拒绝增加至最大;9例(18%)拒绝做出改变,15例(30%)已经达到了最大速率。只产生一例有记录的输血反应(心悸),但是该患者在随后的输血中能够耐受更高的输血速率。使用TWRC的地中海贫血患者安全转用LDRC。输血速率安全地得到提高,计算出减少的白天卧床时间为每月17.45小时。这证实了5 mL/kg/h的指引在心功能得到保护的输血依赖型地中海贫血患者中有良好的耐受性,可以推广至全球其他中心。


BMJ ◽  
1963 ◽  
Vol 1 (5339) ◽  
pp. 1236-1237 ◽  
Author(s):  
C. Y. C. Pak
Keyword(s):  

2021 ◽  
Vol 56 (3) ◽  
pp. 1-7
Author(s):  
Monika Witoszek ◽  
Małgorzata Kalaga

The Yta antigen from the Cartwright blood group system is a high-prevalence antigen found in 99.8% of the population. The literature data shows that antibodies anti-Yta demonstrate the variable clinical significance and are rarely the cause of a hemolytic post-transfusion reaction. The study aims to present the difficulties related to the selection and sustainable supply of blood for transfusion for the patient of the Silesian Centre for Heart Diseases with anti-Yta alloantibodies, qualified for a heart transplant. If Yt(a-) blood is not available Institute of Hematology and Transfusion Medicine in Warsaw, referring to reports in the publications, allowed transfusion of the least incompatible red blood cells in indirect antiglobulin test. One hour after transfusion of leucocyte-depleted concentrate of red blood cells (RBCs), issued in accordance with the above recommendations by Regional Blood Donation Center in Katowice as the least incompatible, the patient was observed to experience symptoms of an adverse post-transfusion reaction. For subsequent transfusions, RBCs from Yt(a-) donors were selected, of which only eight were registered in Poland at that time. Medical decisions on RBCs transfusion in patients for whom no compatible blood can be selected is very difficult, and the benefits of incompatible transfusion should be weighed against the risk of possible complications. To avoid this, it should be remembered that the early identification of antibodies increases the chance of finding serologically compatible blood and in many cases allows to supply blood for a patient with autologous donations.


Sign in / Sign up

Export Citation Format

Share Document